CDC's STD guidelines add botanical treatment

Article

The Centers for Disease Control included a botanical treatment for genital warts in its recently revised 2010 CDC Sexually Transmitted Diseases Treatment Guidelines.

The Centers for Disease Control and Prevention (CDC) included a botanical treatment for genital warts in its recently revised 2010 CDC Sexually Transmitted Diseases (STDs) Treatment Guidelines.

CDC included Veregen (sinecatechins) Ointment 15%, a topical medication for the treatment of external genital and perianal warts, as a new therapeutic option in the guidelines.

Approved by FDA in October 2006, Veregen is derived from green tea leaves from the plant Camellia sinensis (L.) O Kuntze and contains a proprietary mixture of catechins and other green-tea components. Catechins reportedly have antioxidative, immunostimulatory, and antiviral properties, according to PharmaDerm, the manufacturer of Veregen.

Other patient-applied treatments recommended for external genital warts in the new treatment guidelines are podofilox 0.5% solution or gel and imiquimod 5% cream.

CDC’s STD Treatment Guidelines were revised after CDC met in Atlanta in April 2009 with a group of professionals knowledgeable in the field of STDs.

The updated guidelines feature new information on the expanded diagnostic evaluation for cervicitis and trichomoniasis; new treatment recommendations for bacterial vaginosis and genital warts; the clinical efficacy of azithromycin for chlamydial infections in pregnancy; the role of Mycoplasma genitalium and trichomoniasis in urethritis/cervicitis and treatment-related implications; the increasing prevalence of antimicrobial-resistant Neisseria gonorrhoeae; the sexual transmission of hepatitis C; and approaches to STD prevention.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.